<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8900963</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1466</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Neurobiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Neurobiol.</journal-id>
<journal-title-group>
<journal-title>Molecular neurobiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-7648</issn>
<issn pub-type="epub">1559-1182</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30187385</article-id>
<article-id pub-id-type="pmc">6401336</article-id>
<article-id pub-id-type="doi">10.1007/s12035-018-1330-3</article-id>
<article-id pub-id-type="manuscript">NIHMS1505896</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Allopregnanolone treatment improves plasma metabolomic profile associated with GABA metabolism in Fragile X-associated Tremor/Ataxia Syndrome: a pilot study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Napoli</surname>
<given-names>Eleonora</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schneider</surname>
<given-names>Andrea</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Jun Yi</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trivedi</surname>
<given-names>Aditi</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carrillo</surname>
<given-names>Nika Roa</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rogawski</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Hagerman</surname>
<given-names>Randi J.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Giulivi</surname>
<given-names>Cecilia</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Molecular Biosciences, University of California Davis, School of Veterinary Medicine, Davis, CA</aff>
<aff id="A2"><label>2</label>Department of Pediatrics, School of Medicine, University of California Davis, Sacramento, CA</aff>
<aff id="A3"><label>3</label>UC Davis MIND Institute, UC Davis Health, Sacramento, CA</aff>
<aff id="A4"><label>4</label>Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA</aff>
<aff id="A5"><label>5</label>School of Medicine, University of California Davis, Sacramento, CA</aff>
<aff id="A6"><label>6</label>Department of Neurology, School of Medicine, University of California Davis, Sacramento, CA</aff>
<author-notes>
<fn fn-type="con" id="FN1">
<p id="P1">Author contribution</p>
<p id="P2">EN assessed most of the mitochondrial outcomes, helped drafting, edited and approved the final version of the manuscript; AS carried out cognitive and psychological testing on the patients, revised the manuscript and approved the final manuscript; JW acquired neuroimaging data, performed statistical analysis, and interpreted the results, reviewed and approved the final version of the manuscript; AT and NRC analyzed neuropsychiatric tests, reviewed and approved the final version of the final version of the manuscript; FT provided lymphocytes, performed the genotyping, revised and approved the manuscript; MR provided expertise in intravenous injection of allopregnanolone, reviewed the manuscript and approved its final version; RH carried out clinical assessment of these subjects, wrote clinical findings, revised and approved the final version of the manuscript; CG conceptualized the study, designed the experiments, analyzed the metabolomics data, and wrote the manuscript.</p>
</fn>
<corresp id="CR1"><bold>Correspondence</bold>: Dr. Cecilia Giulivi, Department of Molecular Biosciences, 3009 VetMed3B, 1089 Veterinary Medicine Dr., University of California Davis, School of Veterinary Medicine, Davis, CA 95616; <email>cgiulivi@ucdavis.edu</email>; phone: (530)754-8603; fax: (530)754-9342</corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P37">Conflict of interest</p>
<p id="P38">RH has received funding from Novartis, Roche/Genentech, Alcobra, and Neuren for treatment trials in fragile X syndrome, autism and Down syndrome. She has also consulted with Novartis, Fulcrum, Zynerba and Roche/Genentech regarding treatment for fragile X syndrome. The other authors have no conflicts of financial interest relevant to this article to disclose.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>20</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>05</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2020</year>
</pub-date>
<volume>56</volume>
<issue>5</issue>
<fpage>3702</fpage>
<lpage>3713</lpage>
<!--elocation-id from pubmed: 10.1007/s12035-018-1330-3-->
<abstract id="ABS1">
<p id="P3">Currently there is no effective treatment for the Fragile X-associated Tremor/Ataxia Syndrome (FXTAS), a late-onset neurodegenerative disorder. In this pilot study, we evaluated whether allopregnanolone, a natural neurosteroid that exerts beneficial effects in neurodegenerative diseases, nervous system injury and peripheral neuropathies, could improve lymphocytic bioenergetics and plasma pharmacometabolomics in six males with FXTAS (68 ± 3 y old; <italic>FMR1</italic> CGG repeats 94 ± 4; FXTAS stages ranging from 3 to 5) enrolled in a 12-week open-label intervention study conducted at the University of California Davis from December 2015 through July 2016. Plasma pharmacometabolomics and lymphocytic mitochondria function were assessed at baseline (on the day of the first infusion) and at follow-up (at the end of the infusion within 48 h). In parallel, quantitative measurements of tremor and ataxia, and neuropsychological evaluations of mental state, executive function, learning, memory and psychological symptoms were evaluated at the same time points. Allopregnanolone treatment impacted significantly GABA metabolism, oxidative stress and some of the mitochondria-related outcomes. Notably, the magnitude of the individual metabolic response, as well as the correlation with some of the behavioral tests, was overwhelmingly carrier-specific.</p>
<p id="P4">Based on this pilot study, allopregnanolone treatment has the potential for improving cognitive and GABA metabolism in FXTAS aligned with the concept of precision medicine.</p>
</abstract>
<kwd-group>
<kwd>Allopregnanolone</kwd>
<kwd>bioenergetics</kwd>
<kwd>FXTAS</kwd>
<kwd>GABA</kwd>
<kwd>lymphocytes</kwd>
<kwd>pharmacometabolomics</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>